Biotricity Expands Distribution of New Bioheart Device on


Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.

New heart monitoring solution delivers personalized heart health information right to your smartphone

Now easy to buy and use: No prescription needed for an advanced heart and lifestyle solution

REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 / Biotricity Inc. (NASDAQ: BTCY), a modern medical technology company providing innovative remote biometric monitoring solutions, today announced that it has expanded distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring. technology used by doctors, on

Last month, the company launched commercial sales of its Bioheart device. To improve availability and extend reach, Biotricity is now listing it on at: Bioheart on Amazon for $ 199 with a special introductory price of $ 149 for a limited time. You can see the Bioheart heart monitor in use here.

“We aim to transform the heart health market and believe the Bioheart system will play an important role in this effort,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, “The Bioheart device is an important part of our full spectrum, virtual heart clinic “of mobile heart care and lifestyle solutions. It will be fully integrated with a growing number of cardiology practices through our cloud-based Biosphere ecosystem that we plan to fully deploy in 2022, allowing physicians to gain a more holistic view of a patient’s health.

“The ability to offer Bioheart on Amazon extends the availability for the public to easily access the benefits of this exciting technology,” added Dr Waqaas.

The launch of Bioheart opens up a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $ 1.24 billion. Heart disease is intermittent, requiring long-term data collection for effective information and lifestyle management. With continuous monitoring, Bioheart is reinventing personal cardiac management with retrospective snapshots and long-term data collection.

With a revolutionary new feature, users can collect data for hours, days, weeks, months and even years! They can create snapshots of rhythm data by examining past data and tagging it for personal recordings. These are one-of-a-kind features that will help individuals examine their data for a better understanding of the impact on their lifestyle and heart health.

Bioheart features include:

  • Integrated dry contacts for data collection
  • Advanced data collection – three different heart views
  • Continuous recording of the rhythm 24/7
  • 48 hour battery life
  • Custom analyzes
  • Bluetooth connected

With the Bioheart smartphone app, users can:

  • View the electrical heart rate live on the app
  • View data on advanced heart measurements such as electrical heart rate, heart rate, and heart rate variability
  • View historical heart rate ranges
  • Create a heart rate diary and save snapshots of heart activity
  • Easily create retrospective snapshots, a unique feature
  • Easily export and share heart data with a doctor

Bioheart incorporates the company’s proprietary advanced cardiac technology, combined with powerful analytics and continuous rhythm recording, to help individuals understand and improve their heart health. Individuals can track their heart statistics 24/7 with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.

Bioheart retails for $ 199 and is available for the special price of $ 149, for a limited time, on Amazon or The application is available on the Apple App Store and on Google Play.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap between remote monitoring and chronic care management. Physicians and patients trust Biotricity’s unmatched standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic disease. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit

The Bioheart name, logo and taglines are trademarks of Biotricity Inc. US and international patents pending. Bioheart does not require a prescription.

Bioheart does not diagnose, treat, or repair heart disease. Bioheart is not intended to be a diagnostic tool, or for clinical use, or clinical interpretation, and is intended to be a lifestyle and wellness solution for individuals. If users of the Bioheart are concerned about the data obtained from the device, they should consult a healthcare practitioner directly for further advice. Biotricity disclaims any representation made, explicitly or implicitly, which would suggest that the accuracy of the data obtained lends itself to clinical interpretation.

Bioheart as described here, and later versions, may or may not be the same as advertised and may or may not differ in features and functionality. All statements made here about Bioheart, its specifications, its functionality are based on the design and concepts the company considers feasible, but the functionality may be different.

Important Cautions Regarding Forward-Looking Statements

All statements in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “may”, “should”, “would”, “will”, “could”, “,” “Expect”, “anticipate”, “estimate”, “believe”, “intend”, “seek”, “project” or “objective” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) management’s plans, objectives and goals for future operations, including plans, objectives or goals relating to the design, development and marketing of Bioflux or any other Company project products or services, (ii) a projection of income (including income / loss), profits (including profits / losses) per share, capital expenditure, dividends, capital structure or other financial elements, (iii) the future financial performance of the Company, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions under – adjacent or linked to any declaration described in points (i), (ii), (iii) or (iv) above. These forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances and may not be made because they are based on current projections, plans, objectives, beliefs, expectations, estimates and assumptions. of the Company and are subject to a number of risks and uncertainties and other influences, over which the Company has no control. The actual results and timing of certain events and circumstances may differ materially from those described in forward-looking statements due to these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the inability of the Company to obtain additional funding, the length of time and significant resources associated with the development of its products and the resulting insufficient cash flow and resulting illiquidity, the Company’s inability to develop its business, significant government regulation of medical devices and healthcare sector, lack of product diversification, existing or increased competition, results of arbitration and litigation, volatility and illiquidity of shares, and the failure of the Company to implement plans or the Company’s business strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There can be no assurance that the Company will ever become profitable. During the quarter ended June 30, 2020, the Company incurred a net loss attributable to common shareholders of $ 3.4 million. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this press release.

[email protected]

Investor Relations
Biotricity Investor Relations
[email protected]

Marc Forney
MKR Group, Inc.
12198, boulevard Ventura, bureau 200
Los Angeles, California 91604
[email protected]

THE SOURCE: Biotricity, Inc.

See the source version on


About Catriona

Check Also

Should we be pleased with New Jersey Resources Corporation’s (NYSE:NJR) 12% ROE?

One of the best investments we can make is in our own knowledge and skills. …